Catecholamines and neurologic diseases (second of two parts).
D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D001927:Brain Diseases / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism*; D002561:Cerebrovascular Disorders / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004402:Dysautonomia, Familial / Q000378:metabolism; D004422:Dystonia Musculorum Deformans / Q000378:metabolism; D006501:Hepatic Encephalopathy / Q000378:metabolism; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use; D009069:Movement Disorders / Q000378:metabolism; D009103:Multiple Sclerosis / Q000378:metabolism; D009422:Nervous System Diseases / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism; D010661:Phenylketonurias / Q000378:metabolism; D012640:Seizures / Q000378:metabolism; D013119:Spinal Cord Injuries / Q000378:metabolism; D014103:Torticollis / Q000378:metabolism; D005879:Tourette Syndrome / Q000378:metabolism
D002395:Catecholamines; D007980:Levodopa; D004298:Dopamine; D006719:Homovanillic Acid